← Leaderboards
Elizabeth Mittendorf
University Of Tx Md Anderson Can Ctr
$2,397,186
Attributed
$2,397,186
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $502.9K · FY2008–18$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$2,397,186 · 3
By mechanism
U54$1,405,378 · 1
R00$719,648 · 1
K99$272,160 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Khandan Keyomarsi$13,000,468
- Ruy Lopez Ridaura$1,748,418
- Rahul Anil Sheth$2,509,641
- Kelly K Hunt$5,274,757
- Michael Paul Kim$1,757,817
Others in their field
Top investigators on “Therapeutic Agents”
- David Heimbrook · Leidos Biomedical Research, Inc.$386,032,874
- Gregory H Reaman · National Childhood Cancer Foundation$247,684,034
- Leonard Freedman · Leidos Biomedical Research, Inc.$239,520,687
- Sharon A Nachman · Johns Hopkins University$213,337,729
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$208,842,121
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$197,687,122
Research focus
Therapeutic AgentsErbb2 GeneCancer PatientMalignant NeoplasmsBaseAffectIn VivoResponseCancer TherapyTumorTreatment StrategyMalignant Breast NeoplasmBreast Cancer CellBreastDown-RegulationBiologyBiological ModelsAlgorithmsElastasesClinically RelevantCyclin EAnticancer ResearchCareerEnsure
Grant awards (8)
Transport of Effector T cells and Nano-DC vaccine in Breast Cancer$467,748
U54 · FY2018 · CA · contact PI
Transport of Effector T cells and Nano-DC vaccine in Breast Cancer$434,685
U54 · FY2017 · CA · contact PI
Transport of Effector T cells and Nano-DC vaccine in Breast Cancer$502,945
U54 · FY2016 · CA · contact PI
Cyclin E: Implications for targeted therapy in HER2-overexpressing breast cancer$233,214
R00 · FY2012 · CA · contact PI
Cyclin E: Implications for targeted therapy in HER2-overexpressing breast cancer$237,434
R00 · FY2011 · CA · contact PI
Cyclin E: Implications for targeted therapy in HER2-overexpressing breast cancer$249,000
R00 · FY2010 · CA · contact PI
Cyclin E: Implications for targeted therapy in HER2-overexpressing breast cancer$136,080
K99 · FY2009 · CA · contact PI
Cyclin E: Implications for targeted therapy in HER2-overexpressing breast cancer$136,080
K99 · FY2008 · CA · contact PI